Coagulation factor IX gene (F9) (F9)

The F9 genomic locus, located on the X chromosome (Xq27.1), encodes Coagulation Factor IX, a vitamin K-dependent serine protease essential for the intrinsic pathway of blood coagulation (NCBI Gene ID: 2158). Mutations in this locus lead to Hemophilia B, a bleeding disorder characterized by deficient or dysfunctional Factor IX protein (UniProt P00740). In the context of hepatocyte nuclear DNA, this locus is a primary target for liver-directed gene therapies, which aim to restore endogenous production of Factor IX by introducing a functional copy of the gene or editing the existing sequence. Modern therapeutic approaches, such as adeno-associated virus (AAV) vector-mediated gene transfer, specifically target hepatocytes to leverage their natural protein synthesis and secretion machinery (FDA, 2022). Successful targeting of this locus results in the secretion of Factor IX into the bloodstream, potentially providing a long-term cure for patients with Hemophilia B (FDA, 2024). Safety considerations include the risk of immune-mediated hepatotoxicity and the theoretical potential for insertional mutagenesis within the nuclear DNA. Monitoring of liver enzymes and Factor IX activity levels is crucial for assessing the efficacy and safety of drugs targeting this locus. This target represents a significant advancement in precision medicine, moving from protein replacement to genetic correction.

Other names

F9 genomic locusFactor IX geneFIX geneHEMB locusChristmas factor geneCoagulation factor IX genomic locus

Gene addition via adeno-associated virus (AAV) vector delivery to hepatocytes, resulting in the expression of a functional Factor IX protein from the hepatocyte nucleus (FDA, 2022; FDA, 2024).